None
Quote | EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT)
Last: | $8.93 |
---|---|
Change Percent: | -1.82% |
Open: | $8.96 |
Close: | $8.93 |
High: | $9.19 |
Low: | $8.45 |
Volume: | 699,613 |
Last Trade Date Time: | 07/22/2024 03:00:00 am |
News | EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT)
– Two New Independent Directors, Stuart Duty and Andrew Saik, Appointed – Third New Independent Director to Be Appointed to Board in Near Term MONTREAL and CHARLOTTE, N.C., July 15, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) (...
– Phase 3 trial design for the LUGANO and LUCIA pivotal non-inferiority trials of DURAVYU in wet AMD based on positive EOP2 meeting with FDA; on track for trial initiation in 2H 2024 – – Positive twelve-month safety and efficacy data from Phase 2 DAVIO 2 clinical tria...
Message Board Posts | EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $EYPT News Article - EyePoint Pharmaceuticals Reports First Quarter 2023 Financial Resu | whytestocks | investorshangout | 05/03/2023 2:25:48 PM |
whytestocks: $EYPT News Article - EyePoint Pharmaceuticals to Report First Quarter 2023 Financial Re | whytestocks | investorshangout | 04/26/2023 12:10:49 PM |
znewcar1: $EYPT 58% v22,7M c9.00 f34,3M H10.41 S7.4 | znewcar1 | investorshangout | 04/22/2023 3:00:22 AM |
whytestocks: $EYPT News Article - EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT) Near the Top of Equit | whytestocks | investorshangout | 04/21/2023 6:35:46 PM |
znewcar1: This hit a H in the video of 18 and yet the vol is different Not sure of the float then ye | znewcar1 | investorshangout | 04/21/2023 2:27:08 PM |
News, Short Squeeze, Breakout and More Instantly...
EyePoint Pharmaceuticals Inc. Company Name:
EYPT Stock Symbol:
NASDAQ Market:
EyePoint Pharmaceuticals Inc. Website:
– Two New Independent Directors, Stuart Duty and Andrew Saik, Appointed – Third New Independent Director to Be Appointed to Board in Near Term MONTREAL and CHARLOTTE, N.C., July 15, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) (...
– Phase 3 trial design for the LUGANO and LUCIA pivotal non-inferiority trials of DURAVYU in wet AMD based on positive EOP2 meeting with FDA; on track for trial initiation in 2H 2024 – – Positive twelve-month safety and efficacy data from Phase 2 DAVIO 2 clinical tria...
WATERTOWN, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company will host an R...